Arcutis-linked roflumilast foam faces a 10-patient HS test with no active comparator
A Tulane-run Phase 2 proof-of-concept trial of ZORYVE foam 0.3% in hidradenitis suppurativa will read out a gene-expression endpoint in a field with no other PDE4 program past Phase 2.
Executive Summary
- A small, single-arm study is testing whether Arcutis's approved topical PDE4 inhibitor can produce a measurable biological and clinical signal in a fourth inflammatory skin indication where it is not yet approved.
- The design, a small uncontrolled cohort measuring a gene-expression biomarker, is built to generate a go/no-go signal for further development, not to establish efficacy on its own.
- Hidradenitis suppurativa is being pursued mostly by biologics and JAK inhibitors; this is one of very few PDE4-directed efforts to reach clinical testing in the disease, leaving the mechanism with limited direct human precedent here.
- Enrollment and protocol activity have moved on schedule since the trial opened, and the readout timing is now a disclosure question rather than an execution question.
The trial
NCT07077902 is a Phase 2, single-arm study evaluating ZORYVE foam 0.3% (roflumilast) in adults with hidradenitis suppurativa who have failed systemic antibiotic, hormonal, immunomodulatory, or biologic therapy. The trial targets 10 patients, is recruiting in the United States, and lists a primary completion date of September 1, 2026. Its primary endpoint measures the change in gene expression profile at week 16 versus baseline, a biomarker readout rather than a clinical response measure; three secondary endpoints cover pain score, quality of life, and overall response rate. Arcutis said in its first-quarter 2026 update that it expects to report results from this proof-of-concept study in the first quarter of 2027. NCT07077902+1A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis SuppurativaNCT07077902Arcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why the design matters
The trial has no comparator arm and no randomization: 10 patients on one treatment, with response judged against their own baseline. That makes the study useful for deciding whether to advance roflumilast foam into a larger, controlled program in hidradenitis suppurativa, but it is not built to establish efficacy on its own. A gene-expression shift at week 16, paired with directional movement on pain score and response rate, would be the signal that supports moving forward; a null result on the biomarker endpoint would be a more direct read on whether the mechanism engages the target tissue in this disease. NCT07077902A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis SuppurativaNCT07077902
The competitive field
Hidradenitis suppurativa's active pipeline is dominated by biologics and JAK inhibitors: AbbVie's upadacitinib and Novartis's remibrutinib are both in Phase 3, alongside Incyte's povorcitinib and MoonLake's sonelokimab in earlier-stage testing. None of these share roflumilast's PDE4 target. Within PDE4 specifically, the target-by-indication landscape shows three trials and three sponsors have tested PDE4 in hidradenitis suppurativa, with a maximum phase of Phase 2, indicating this mechanism has only reached early clinical testing in the disease. Arcutis's roflumilast is already approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis under the ZORYVE brand, so this readout tests indication extension for an established molecule rather than a new mechanism entering the clinic. ArcutisArcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026
Operational status
The trial moved from Not yet recruiting to Recruiting on December 23, 2025, and enrollment has held flat at its target of 10 patients with no growth or contraction flagged against the trial's own design. Registry activity shows no primary-completion-date changes, no endpoint amendments, and no eligibility-criteria changes since the study posted, a stable protocol history consistent with a trial proceeding on its original plan. The primary completion date of September 1, 2026 falls before the stated Q1 2027 disclosure window, so data collection itself is not the constraint on when results become public. NCT07077902A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis SuppurativaNCT07077902
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.